Sac-TMT plus fruquintinib for second-line stomach cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs—Sac-TMT and fruquintinib—as second-line treatment for advanced stomach or gastroesophageal junction cancer. It is for people whose cancer progressed after one prior chemotherapy regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Your cancer got worse during or within 6 months after your first chemotherapy (or after adjuvant chemo).
- You have at least one tumor that can be seen on a scan (not just skin or bone spots).
- You are in fairly good health (able to do daily activities without help) and have adequate organ function.
- You haven't had certain prior treatments targeting TROP2, topoisomerase I inhibitors, or VEGFR.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This clinical trial is testing a combination of three drugs—sintilimab, fruquintinib, and standard chemotherapy—as a first treatment for advanced stomach cancer that cannot be surgically removed. The goal is to see if this combination can shrink the cancer enough to allow surgery, potentially improving outcomes.
This trial tests a combination of two medications—fruquintinib (a targeted therapy) and a PD-1 inhibitor (immunotherapy)—as a first maintenance treatment after initial chemotherapy for advanced gastric cancer. The goal is to see if this combination can help control the cancer longer.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.